Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
16.4
Year-on-year change in net sales (%)Wording
Conditional
How definitive the wording is.Results for this period
Full year2023年9月1日〜2024年8月31日ConsolidatedJapanese GAAPNet Sales28,513¥ millionYear on year +16.4%Progress 94.4%
Operating profit8,392¥ millionYear on year +15.8%Progress 94.3%
Ordinary income8,464¥ millionYear on year +5.9%Progress 95.6%
Net income attributable to owners of the parent6,286¥ millionYear on year +5.4%Progress 99.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥63.82
Financial position at period-end
Total assets57,177¥ million
of which net assets 52,330 ¥ million
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Cash inflows and outflows
Operating+7,810
Investment-6,642
Financials-3,703
Net change-2,535
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥21,017 million
Segment revenueSurgical-related products ¥8,152 million (YoY +20.2%), Ailess needle-related products ¥10,222 million (YoY +19.2%), Dental Products ¥10,139 million (YoY +11.1%)
Segment profitSurgical-related products ¥2,640 million (YoY +24.5%), Ailess needle-related products ¥3,872 million (YoY +35.2%), Dental Products ¥1,878 million (YoY -16.8%)
Regional salesRegion Japan / Net Sales for the Current Period ¥4,206 million / Prior-Period Net Sales ¥4,165 million, Region North America / Net Sales for the Current Period ¥2,785 million / Prior-Period Net Sales ¥2,033 million, Region Europe / Net Sales for the Current Period ¥5,563 million / Prior-Period Net Sales ¥5,337 million / 内ドイツ Current fiscal year 1,572 / Previous period 1,348, Region Asia / Net Sales for the Current Period ¥13,894 million / Prior-Period Net Sales ¥11,059 million / 内中国 Current fiscal year 8,643 / Previous period 6,656, Region Other / Net Sales for the Current Period ¥2,064 million / Prior-Period Net Sales ¥1,892 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥30,200 million (YoY +5.9%)
Operating profit¥8,900 million (YoY +6.1%)
Ordinary income¥8,850 million (YoY +4.6%)
Net income¥6,350 million (YoY +1.0%)
Annual Dividend Forecast¥39 per share → ¥39 per share（0.0%）
Payout ratio61.1
Shareholder Return Policy現在の配当性向（2024年8月期時点で61.1％）を維持する方針
Factors Behind Changes in Business Performance
アジア、北米を中心とした販売増加と円安による海外売上高の押し上げにより売上高が増加した。海外子会社の製造原価、マーケティング強化に伴う販促費、本社人件費は増加したが、売上高の拡大が費用増を吸収した。
Disclosure regarding the going concern assumption
No applicable matters
Material subsequent eventsNo applicable matters.
Impairment loss¥56 million
Breakdown of extraordinary income (loss)Extraordinary income Insurance surrender value ¥26 million, Gain on sale of non-current assets ¥5 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥15 million, Impairment Losses ¥56 million
Depreciation and amortization¥2,270 million
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2023年9月1日〜2024年8月31日 |
| Net Sales | ¥28,513 million (YoY +16.4%) |
| Operating profit | ¥8,392 million (YoY +15.8%) |
| Ordinary income | ¥8,464 million (YoY +5.9%) |
| Profit attributable to owners of the parent | ¥6,286 million (YoY +5.4%) |
| Net income per share | ¥63.82 |
| Total assets | ¥57,177 million |
| Net assets | ¥52,330 million |
| Cash flows from operating activities | ¥7,810 million |
| Cash flows from investing activities | ¥-6,642 million |
| Cash flows from financing activities | ¥-3,703 million |
| Cash and cash equivalents at end of period | ¥21,017 million |
| Full-year earnings forecast | Net Sales ¥30,200 million (YoY +5.9%) / Operating profit ¥8,900 million (YoY +6.1%) / Ordinary income ¥8,850 million (YoY +4.6%) / Net income ¥6,350 million (YoY +1.0%) |
| Annual Dividend Forecast | ¥39 per share → ¥39 per share（0.0%） |
| Payout ratio | 61.1 |
| Shareholder Return Policy | 現在の配当性向（2024年8月期時点で61.1％）を維持する方針 |
| Segment revenue | Surgical-related products ¥8,152 million (YoY +20.2%), Ailess needle-related products ¥10,222 million (YoY +19.2%), Dental Products ¥10,139 million (YoY +11.1%) |
| Segment profit | Surgical-related products ¥2,640 million (YoY +24.5%), Ailess needle-related products ¥3,872 million (YoY +35.2%), Dental Products ¥1,878 million (YoY -16.8%) |
| Regional sales | Region Japan / Net Sales for the Current Period ¥4,206 million / Prior-Period Net Sales ¥4,165 million, Region North America / Net Sales for the Current Period ¥2,785 million / Prior-Period Net Sales ¥2,033 million, Region Europe / Net Sales for the Current Period ¥5,563 million / Prior-Period Net Sales ¥5,337 million / 内ドイツ Current fiscal year 1,572 / Previous period 1,348, Region Asia / Net Sales for the Current Period ¥13,894 million / Prior-Period Net Sales ¥11,059 million / 内中国 Current fiscal year 8,643 / Previous period 6,656, Region Other / Net Sales for the Current Period ¥2,064 million / Prior-Period Net Sales ¥1,892 million |
| Depreciation and amortization | ¥2,270 million |
| Impairment loss | ¥56 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Insurance surrender value ¥26 million, Gain on sale of non-current assets ¥5 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥15 million, Impairment Losses ¥56 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Material subsequent events | No applicable matters. |
| Factors Behind Changes in Business Performance | アジア、北米を中心とした販売増加と円安による海外売上高の押し上げにより売上高が増加した。海外子会社の製造原価、マーケティング強化に伴う販促費、本社人件費は増加したが、売上高の拡大が費用増を吸収した。 |
Items this document does not state (10)
Operating MarginEquity ratioRevision to Earnings ForecastOrders received and order backlogChange in accounting policyChanges in the scope of consolidationAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.主にアジア、北米を中心とした地域で販売が増加したこと、円安による海外売上高の押し上げがあったこと。海外子会社の製造原価、販促費、本社人件費は増加したが、売上高の拡大が費用増を吸収した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.